Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?
Rasonque is off to an impressive start. Here’s what that could mean for Revolution Medicines.
Revolution Medicines (RVMD) is making waves in the biotech world, having recently earned approval for Rasonque, a groundbreaking drug for pancreatic cancer. The drug targets RAS-addicted cancers, a group that has historically been difficult to treat. In a Phase 3 study, Rasonque outperformed the standard chemotherapy treatment, increasing median overall survival from 6.7 months to 13.2 months in patients with previously treated metastatic pancreatic cancer.
Since its approval in late August, Rasonque has generated $198 million in revenue in just three and a half weeks, marking one of the strongest launches in the oncology drug market. Currently, the company has a market cap of $34.8 billion, but shares have declined about 29% since Rasonque's approval. This suggests that the market cap from several months ago may have been justified, with analysts now expecting the company to generate $3 billion in revenue next year, trading at 11.6x estimated 2027 sales.
Revolution Medicines has multiple Phase 3 clinical trials underway, including trials for two other investigational medicines. If Rasonque experiences a strong commercial ramp-up and the company makes significant clinical progress, shares could maintain strong momentum. The U.S. market alone is estimated to generate about 55,000 new cases of metastatic pancreatic cancer annually, which justifies Revolution Medicines' current valuation.
Considering the strong clinical progress, a robust pipeline, and the potential for approvals in other countries, the stock is worth buying and holding for at least the next five years. With a market cap of $34.8 billion, the potential upside makes Revolution Medicines an attractive opportunity for investors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.